3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
5
Plasma cell
3
Lymphoid
3
Sarcoma
2
Other hematologic neoplasm
2
Gynecologic
2
Genitourinary
2
Gastrointestinal
1
Conditions
Colorectal Neoplasms
713
Pancreatic Neoplasms
500
Carcinoma, Hepatocellular
333
Colonic Neoplasms
282
Stomach Neoplasms
278
Rectal Neoplasms
236
Esophageal Neoplasms
198
Neoplasms
194
Liver Neoplasms
169
Neoplasm Metastasis
164
Carcinoma, Non-Small-Cell Lung
125
Breast Neoplasms
111
Cholangiocarcinoma
91
Ovarian Neoplasms
87
Lung Neoplasms
85
Gastrointestinal Neoplasms
80
Melanoma
76
Gastrointestinal Stromal Tumors
68
Adenocarcinoma Of Esophagus
64
Adenocarcinoma
62
Prostatic Neoplasms
59
Biliary Tract Neoplasms
58
Carcinoma, Renal Cell
56
Sarcoma
54
Head and Neck Neoplasms
54
Urinary Bladder Neoplasms
51
Gallbladder Neoplasms
49
Barrett Esophagus
49
Bile Duct Neoplasms
47
Anus Neoplasms
47
Interventions
N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Peripheral Nervous System Diseases
×
Gastrointestinal
×
Clear all
NCT04034355
2022-01-26
POLAR-A
Egetis Therapeutics
Phase 3
Terminated
301 enrolled
18 charts